All In MedTech

FDA Clearance Tracker · P080011-S139

Biofinity Toric Multifocal

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Jun 9, 2022 (this decision)Source: openFDAMethods & limitations

PMA supplement

The decision

FDA number
P080011-S139
Device name
Biofinity Toric Multifocal
Applicant location
San Ramon, CA
Received
Feb 25, 2022
Decided
Jun 9, 2022
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Location Change - Manufacturer/Sterilizer/Packager/Supplier
Original approval
P080011

Device type

Device class
Class III
Regulation
21 CFR 886.5925
Specialty
Ophthalmology

Every decision under product code LPM

FDA's approval statement

As written in FDA's record.

Aapproval for the addition of the CooperVision, Inc. facility located at 711 North Road, Scottsville, New York 14546 as a manufacturing site for Biofinity Torie Multi focal.

Source documents

Other decisions for CooperVision, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.